Compare CYRX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYRX | ENTA |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 374.6M |
| IPO Year | 2008 | 2012 |
| Metric | CYRX | ENTA |
|---|---|---|
| Price | $10.55 | $13.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $13.31 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 409.4K | 106.1K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | 29.93 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | $102,814,000.00 |
| Revenue This Year | $11.06 | $7.76 |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | $7.28 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $5.31 | $4.96 |
| 52 Week High | $11.45 | $17.15 |
| Indicator | CYRX | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 68.70 | 46.53 |
| Support Level | $9.18 | $13.02 |
| Resistance Level | $11.33 | $13.76 |
| Average True Range (ATR) | 0.41 | 0.67 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 82.83 | 22.97 |
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.